CARIS LIFE SCIENCES, INC. Revenue
CARIS LIFE SCIENCES, INC. (CAI) reported Revenue of $263.71 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2026-08-05
- CARIS LIFE SCIENCES, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-06-30 was $263.71M, a 45.38% increase year-over-year.
- CARIS LIFE SCIENCES, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-03-31 was $216.17M, a 78.78% increase year-over-year.
- CARIS LIFE SCIENCES, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-12-31 was $292.89M, a 125.44% increase year-over-year.
- CARIS LIFE SCIENCES, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-09-30 was $216.83M, a 113.38% increase year-over-year.
- CARIS LIFE SCIENCES, INC. revenue from contract with customer, excluding assessed tax for fiscal 2025 was $812.03M, a 96.97% increase from fiscal 2024.
- CARIS LIFE SCIENCES, INC. revenue from contract with customer, excluding assessed tax for fiscal 2024 was $412.26M, a 34.67% increase from fiscal 2023.
- CARIS LIFE SCIENCES, INC. revenue from contract with customer, excluding assessed tax for fiscal 2023 was $306.13M.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | $263.71M 10-Q · filed 2026-08-05 | $479.89M 10-Q · filed 2026-08-05 | $772.77M derived: sum of 3 quarters · filed 2026-08-05 | $989.61M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $216.17M 10-Q · filed 2026-05-08 | $509.06M derived: sum of 2 quarters · filed 2026-05-08 | $725.89M derived: sum of 3 quarters · filed 2026-05-08 | $907.29M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $292.89M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $509.72M derived: sum of 2 quarters · filed 2026-03-03 | $691.12M derived: sum of 3 quarters · filed 2026-08-05 | $812.03M 10-K · filed 2026-03-03 |
| 2025-09-30 | $216.83M 10-Q · filed 2025-11-05 | $398.23M derived: sum of 2 quarters · filed 2026-08-05 | $519.15M 10-Q · filed 2025-11-05 | $649.06M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $181.40M 10-Q · filed 2026-08-05 | $302.31M 10-Q · filed 2026-08-05 | $432.23M derived: sum of 3 quarters · filed 2026-08-05 | $533.85M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $120.92M 10-Q · filed 2026-05-08 | $250.83M derived: sum of 2 quarters · filed 2026-05-08 | $352.45M derived: sum of 3 quarters · filed 2026-05-08 | $452.50M derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | $129.91M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $231.53M derived: sum of 2 quarters · filed 2026-03-03 | $331.58M derived: sum of 3 quarters · filed 2026-03-03 | $412.26M 10-K · filed 2026-03-03 |
| 2024-09-30 | $101.62M 10-Q · filed 2025-11-05 | $201.67M derived: sum of 2 quarters · filed 2025-11-05 | $282.35M 10-Q · filed 2025-11-05 | |
| 2024-06-30 | $100.05M 10-Q · filed 2025-08-12 | $180.73M 10-Q · filed 2025-08-12 | ||
| 2023-12-31 | $306.13M 10-K · filed 2026-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RadNet, Inc. (RDNT) | United States | $5.611B | -229.65 |
| GRAIL, Inc. (GRAL) | United States | $5.591B | -7.78 |
| VERACYTE, INC. (VCYT) | United States | $3.904B | 41.21 |
| Celcuity Inc. (CELC) | United States | $3.887B | -22.62 |
| CareDx, Inc. (CDNA) | United States | $3.174B | 13.21 |
| Fortrea Holdings Inc. (FTRE) | United States | $1.903B | -19.43 |
| Personalis, Inc. (PSNL) | United States | $1.769B | -13.30 |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |